MSCM
CERE

McElhenny Sheffield Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

McElhenny Sheffield Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13
Closed -$410 – 651
2022
Q4 		$410 Buy
+13
New +$367 ﹤0.01% 644

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

McElhenny Sheffield Capital Management's CERE Position: Q1 2023 in Review

McElhenny Sheffield Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2023, closing a stake of 13 shares — an estimated $410 sold.

McElhenny Sheffield Capital Management first reported a position in CERE in Q4 2022 and held it in 1 quarter. The position peaked at $410 in Q4 2022. 119 funds tracked by Wall St. Rank hold CERE as of Q1 2023.

  • McElhenny Sheffield Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • McElhenny Sheffield Capital Management sold 13 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2023, an estimated $410.
  • McElhenny Sheffield Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • McElhenny Sheffield Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $410 in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2023.

Based on McElhenny Sheffield Capital Management's 13F filing for Q1 2023, filed 13 Apr 2023.